# Daan J A Crommelin

List of Publications by Year
in descending order



| 30 | 3,567 | 346980 22 | 488211 31 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 33 | 33 | 33 | 4463 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?. Journal of Pharmaceutical Sciences, 2022, 111, 861-867. | 1.6 | 30 |
| 2 | Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nature Nanotechnology, 2022, 17, 337-346. | 15.6 | 74 |
| 3 | A Cluster of Articles in Memory of Wim Jiskoot, Ph.D.. Journal of Pharmaceutical Sciences, 2022, 111, 859-860. | 1.6 | 0 |
| 4 | Addressing the Cold Reality of mRNA Vaccine Stability. Journal of Pharmaceutical Sciences, 2021, 110, 997-1001. | 1.6 | 302 |
| 5 | The impact of uncertainty on predictions of the CovidSim epidemiological code. Nature Computational Science, 2021, 1, 128-135. | 3.8 | 45 |
| 6 | mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. International Journal of Pharmaceutics, 2021, 601, 120586. | 2.6 | 647 |
| 7 | Shifting Paradigms Revisited: Biotechnology and the Pharmaceutical Sciences. Journal of Pharmaceutical Sciences, 2020, 109, 30-43. | 1.6 | 8 |
| 8 | The role of liposomes in clinical nanomedicine development. What now? Now what?. Journal of Controlled Release, 2020, 318, 256-263. | 4.8 | 226 |
| 9 | Building Confidence in Simulation: Applications of EasyVVUQ. Advanced Theory and Simulations, 2020, 3, 1900246. | 1.3 | 21 |
| 10 | Introducing VECMAtk - Verification, Validation and Uncertainty Quantification for Multiscale and HPC Simulations. Lecture Notes in Computer Science, 2019, , 479-492. | 1.0 | 14 |
| 11 | Editorial: Public-Private Partnerships as Drivers of Innovation in Healthcare. Frontiers in Medicine, 2019, 6, 114. | 1.2 | 8 |
| 12 | Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: â€œDrug Products, Including Biological Products, that Contain Nanomaterialsâ€. AAPS Journal, 2019, 21, 56. | 2.2 | 28 |
| 13 | Postproduction Handling and Administration of Protein Pharmaceuticals and Potential Instability Issues. Journal of Pharmaceutical Sciences, 2018, 107, 2013-2019. | 1.6 | 75 |
| 14 | Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact. Pharmaceutical Research, 2017, 34, 1985-1999. | 1.7 | 31 |
| 15 | The regulatorâ€™s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?. Multiple Sclerosis Journal, 2016, 22, 47-59. | 1.4 | 8 |
| 16 | Pharmacy preparations: Back in the limelight? Pharmacists make up your mind!. International Journal of Pharmaceutics, 2016, 514, 11-14. | 2.6 | 8 |
| 17 | Cancer nanomedicine: is targeting our target?. Nature Reviews Materials, 2016, 1, . | 23.3 | 154 |
| 18 | Liposomes: The Science and the Regulatory Landscape. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 77-106. | 0.2 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Different Pharmaceutical Products Need Similar Terminology. AAPS Journal, 2014, 16, 11-14. | 2.2 | 53 |
| 20 | How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider. AAPS Journal, 2014, 16, 15-21. | 2.2 | 101 |
| 21 | Towards more effective advanced drug delivery systems1. International Journal of Pharmaceutics, 2013, 454, 496-511. | 2.6 | 124 |
| 22 | Measuring the value of publicâ€“private partnerships in the pharmaceutical sciences. Nature Reviews Drug Discovery, 2012, 11, 419-419. | 21.5 | 15 |
| 23 | Publicâ€“private partnerships in translational medicine: Concepts and practical examples. Journal of Controlled Release, 2012, 161, 416-421. | 4.8 | 15 |
| 24 | How to screen non-viral gene delivery systems in vitro?. Journal of Controlled Release, 2011, 154, 218-232. | 4.8 | 105 |
| 25 | The therapeutic equivalence of complex drugs. Regulatory Toxicology and Pharmacology, 2011, 59, 176-183. | 1.3 | 86 |
| 26 | Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: Essential need to use orthogonal methods to assure the quality of therapeutic protein products. Journal of Pharmaceutical Sciences, 2010, 99, 2200-2208. | 1.6 | 185 |
| 27 | Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. Journal of Pharmaceutical Sciences, 2009, 98, 1201-1205. | 1.6 | 492 |
| 28 | Artificial viruses: a nanotechnological approach to gene delivery. Nature Reviews Drug Discovery, 2006, 5, 115-121. | 21.5 | 318 |
| 29 | Stabilization of Proteins in Dry Powder Formulations Using Supercritical Fluid Technology. Pharmaceutical Research, 2004, 21, 1955-1969. | 1.7 | 97 |
| 30 | Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. International Journal of Pharmaceutics, 2003, 266, 3-16. | 2.6 | 173 |